Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer

Previous studies have shown sex‐related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown. We examined sex‐related differences in the safety of S‐1 plus oxaliplatin (SOX) and S‐1 plus cisplatin (CS) in 663 m...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science Vol. 110; no. 9; pp. 2875 - 2883
Main Authors: Yamada, Yasuhide, Koizumi, Wasaburo, Nishikawa, Kazuhiro, Gotoh, Masahiro, Fuse, Nozomu, Sugimoto, Naotoshi, Nishina, Tomohiro, Amagai, Kenji, Chin, Keisho, Niwa, Yasumasa, Tsuji, Akihito, Imamura, Hiroshi, Tsuda, Masahiro, Yasui, Hirofumi, Fujii, Hirofumi, Yamaguchi, Kensei, Yasui, Hisateru, Hironaka, Shuichi, Shimada, Ken, Hyodo, Ichinosuke
Format: Journal Article
Language:English
Published: England John Wiley & Sons, Inc 01.09.2019
John Wiley and Sons Inc
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Body mass index
Cancer therapies
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Cisplatin - adverse effects
Diarrhea
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Combinations
Enzymes
Female
fluorouracil
Gastric cancer
Gender differences
Humans
Incidence
Leukopenia
Male
Medical prognosis
Metastases
Metastasis
Middle Aged
Nausea
Nausea - chemically induced
Nausea - epidemiology
Neutropenia
Neutropenia - chemically induced
Neutropenia - epidemiology
Original
Oxaliplatin
Oxaliplatin - administration & dosage
Oxaliplatin - adverse effects
Oxonic Acid - administration & dosage
Oxonic Acid - adverse effects
Pharmaceuticals
Potassium
Research funding
sex
Sex differences
Sex Factors
Stomach Neoplasms - blood
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomatitis
Stomatitis - chemically induced
Stomatitis - epidemiology
Studies
S‐1
Tegafur - administration & dosage
Tegafur - adverse effects
Thrombocytopenia
Thrombocytopenia - chemically induced
Thrombocytopenia - epidemiology
Vomiting
Vomiting - chemically induced
Vomiting - epidemiology
oxaliplatin
fluorouracil
gastric cancer
S-1
sex
ISSN:1347-9032, 1349-7006, 1349-7006
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies have shown sex‐related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown. We examined sex‐related differences in the safety of S‐1 plus oxaliplatin (SOX) and S‐1 plus cisplatin (CS) in 663 metastatic gastric cancer patients taking part in a phase III study. The incidences of leukopenia (odds ratio [OR] 1.9; P = .015), neutropenia (OR 2.2; P = .002), nausea (OR 2.0; P = .009), and vomiting (OR 2.8; P < .001) were increased in women versus men treated with SOX, while vomiting (OR 2.9; P < .001) and stomatitis (OR 1.8; P = .043) were increased in women versus men treated with CS. In contrast, male patients treated with CS experienced thrombocytopenia more often (OR 0.51; P = .009). The mean relative dose intensity of S‐1 in SOX was 75.4% in women and 81.4% in men (P = .032). No difference in efficacy was observed between women and men undergoing either regimen. Sex‐related differences in adverse reactions during SOX and CS treatment were confirmed in this phase III study. Further translational research studies are warranted to pursue the cause of this difference. Sex differences in adverse reactions with oral fluoropyrimidine and oxaliplatin or cisplatin were confirmed in a phase III study; further translational research studies are warranted to pursue the causes of this outcome.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/cas.14117